NCT04799054 2026-04-13
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
Clinical Trials
240 trialsNCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
NCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT05394675 2026-03-20
A Study of DS-9606a in Patients With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Terminated
NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT05346484 2026-03-06
MAST
Imugene Limited
Phase 1 Terminated
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT06005974 2026-02-23
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Phase 2 Terminated
NCT06546553 2026-02-23
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
Phase 1 Terminated
NCT05233436 2026-02-19
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT06560645 2026-02-02
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 1 Terminated
NCT06682806 2026-02-02
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 2 Terminated
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT06478862 2026-01-09
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Lipomedix Pharmaceuticals Inc.
Phase 2 Terminated
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
NCT04916002 2025-12-05
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT04844073 2025-12-04
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Takeda
Phase 1/2 Terminated
NCT04725331 2025-11-21
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Phase 1/2 Terminated
NCT05525286 2025-11-17
CLAUDIO-01
Sotio Biotech Inc.
Phase 1/2 Terminated
NCT05798611 2025-11-06
ARTIST
Artios Pharma Ltd
Phase 2 Terminated
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT05646797 2025-10-20
A Study of ASP2074 in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1 Terminated
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT04189445 2025-10-08
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
Phase 2 Terminated
NCT06264921 2025-09-25
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 1 Terminated
NCT04674748 2025-09-24
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
Incyte Corporation
Phase 1 Terminated
NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT03871348 2025-09-10
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT05220098 2025-08-29
First-in-Human Study of TAK-280 in Participants With Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05490043 2025-08-29
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Corporation
Phase 1 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT06877533 2025-08-12
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Terminated
NCT03440437 2025-07-01
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
invoX Pharma Limited
Phase 1/2 Terminated
NCT05274451 2025-07-01
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Phase 1 Terminated
NCT05573035 2025-07-01
A Study to Investigate LYL845 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Phase 1 Terminated
NCT05891197 2025-07-01
START
Lyell Immunopharma, Inc.
Terminated
NCT03248492 2025-06-26
DESTINY-Breast01
Daiichi Sankyo
Phase 2 Terminated
NCT06630247 2025-06-25
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Terminated
NCT04740034 2025-06-17
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Amgen
Phase 1 Terminated
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT04986865 2025-06-09
PROBE
Antengene Corporation
Phase 1 Terminated
NCT04261777 2025-06-03
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Saving Patients' Lives Medical B.V.
Phase 3 Terminated
NCT03505710 2025-05-30
DESTINY-Lung01
Daiichi Sankyo
Phase 2 Terminated